Genetic therapies are delivered to haematopoietic stem cells using targeted lipid nanoparticles.
![](https://cdn.statically.io/img/media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41565-024-01682-6/MediaObjects/41565_2024_1682_Fig1_HTML.png)
References
Tang, L., Huang, Z., Mei, H. & Hu, Y. Signal Transduct. Target. Ther. 1, 306 (2023).
Rosanwo, T. O. & Bauer, D. E. Mol. Ther. 11, 3163–3178 (2021).
Lian, X. et al. Nat. Nanotechnol. https://doi.org/10.1038/s41565-024-01680-8 (2024).
Nakamura, T. et al. Adv. Drug Deliv. Rev. 188, 114417 (2022).
Ware, R. E. Hematology 1, 436–443 (2015).
Wang, X. et al. Nat. Protocols 18, 265–291 (2023).
Liu, K. et al. Nat. Commun. 14, 4007 (2023).
Dimitrievska, M. et al. Blood Rev. https://doi.org/10.1016/j.blre.2024.101185 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.B. is an employee of Sanofi US. M.M.A. declares no competing interests. The views expressed here are those of the authors and do not necessarily reflect the views of their employers.
Rights and permissions
About this article
Cite this article
Bitounis, D., Amiji, M.M. Lipid nanoparticles target haematopoietic stem cells. Nat. Nanotechnol. (2024). https://doi.org/10.1038/s41565-024-01682-6
Published:
DOI: https://doi.org/10.1038/s41565-024-01682-6
- Springer Nature Limited